Teva Pharmaceutical's Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. See why I ...

Rep. Cory Mills (R-FL) sent a letter Tuesday to the chairman of Sichuan Kelun-Biotech Biopharmaceutical, Mr. Liu Gexin, "demanding answers to serious allegations regarding their ties to the Chinese C ...

Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which included revenue from its domestic branded formulation ...

Mr. Kennedy appears to have most Republicans behind him as he seeks the job of health secretary, though he couldn’t escape ...

The Food and Drug Administration’s approval of low-risk tobacco pouches is welcome, but why did it delay for more than four ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, today we look at ...

Cardinal Health's pharmaceutical and specialty solutions segment profit increased 7% to $531 million in the second quarter.